| 0.409 0.028 (7.35%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.52  |
1-year : | 0.63 |
| Resists | First : | 0.44 |
Second : | 0.54 |
| Pivot price | 0.39 |
|||
| Supports | First : | 0.3 | Second : | 0.24 |
| MAs | MA(5) : | 0.38 |
MA(20) : | 0.39 |
| MA(100) : | 0.57 |
MA(250) : | 0.73 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 65 |
D(3) : | 56.7 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 3.27 | Low : | 0.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TRVN ] has closed below upper band by 27.0%. Bollinger Bands are 33.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.42 - 0.42 | 0.42 - 0.42 |
| Low: | 0.37 - 0.37 | 0.37 - 0.37 |
| Close: | 0.41 - 0.41 | 0.41 - 0.41 |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Mon, 01 Apr 2024
Trevena Inc Unveils Updated Corporate Strategy Presentation - TipRanks.com - TipRanks
Wed, 06 Mar 2024
Trevena faces Nasdaq delisting over share price By Investing.com - Investing.com
Thu, 01 Feb 2024
Trevena Inc Elevates Barry Shin to Executive VP and CFO - TipRanks.com - TipRanks
Wed, 15 Nov 2023
Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call Transcript - Yahoo Finance
Mon, 08 May 2023
Why Is Trevena (TRVN) Stock Up 165% Today? - InvestorPlace
Fri, 01 Apr 2022
Trevena Inc (TRVN) Stock: What Does the Chart Say Friday? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -22 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.832e+007 (%) |
| Held by Institutions | 1.81e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.17 |
| Profit Margin | 0 % |
| Operating Margin | 12 % |
| Return on Assets (ttm) | 374.3 % |
| Return on Equity (ttm) | -49.5 % |
| Qtrly Rev. Growth | 14.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -216.2 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.495e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.13 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 112780 |
| Forward Dividend | 81760 |
| Dividend Yield | 27574600% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|